American Journal of Physiology-Heart and Circulatory Physiology · 2009 · 148 citations · 38 references
MedicineCardiologyPharmacologyBiochemical PharmacologyMolecular PharmacologyPharmacodynamicsCardiac BiomarkersCardiac PhysiologyCardiovascular PharmacologyPulmonary HypertensionMechanisms Of Cardiac InjuryMuscle HypertrophyMyocardial Fibrosis DetectionMyocardial Injury AssessmentMyocardial Injury MarkersPulmonary HemodynamicsPulmonary Hypertension PharmacologySystolic Blood Pressure
We investigated the endogenous production of apelin and the cardiac and pulmonary effects of its chronic administration in monocrotaline (MCT)-induced pulmonary hypertension (PH). Male Wistar rats were injected with MCT (60 mg/kg sc) or vehicle (day 0). One week later, these animals were randomly treated during 17 days with pyroglutamylated apelin-13 (Pyr-AP13; 200 microg*kg(-1)*day(-1) ip) or a similar volume of saline, resulting in four groups: sham (n = 11), sham-AP (n = 11), MCT (n = 16), and MCT-AP (n = 13). On day 25, right ventricular (RV) and left ventricular (LV) hemodynamic and morphometric parameters were assessed. Tissue and plasma samples were collected for histological and molecular analysis. When compared with sham, the MCT group presented a significant increase of RV mass (166 +/- 38%), diameter of cardiomyocyte (40 +/- 10%), myocardial fibrosis (95 +/- 20%), peak systolic pressure (99 +/- 22%), peak rate of ventricular pressure rise (dP/dt(max); 74 +/- 24%), peak rate of ventricular pressure decline (dP/dt(min); 73 +/- 19%), and time constant tau (55 +/- 16%). In these animals, RV expression of apelin (-73 +/- 10%) and its receptor APJ (-61 +/- 20%) was downregulated, whereas mRNA expression of type B natriuretic peptide (9,606 +/- 713%), angiotensinogen (191 +/- 147%), endothelin-1 (RV, 497 +/- 156%; and LV, 799 +/- 309%), plasmatic levels of apelin (104 +/- 48%), and angiotensin 1-7 (161 +/- 151%) were increased. Chronic treatment with Pyr-AP13 significantly attenuated or normalized these changes, preventing apelin-APJ mRNA downregulation and PH-induced neurohumoral activation of several vasoconstrictors, which exacerbates apelin-APJ vasodilator effects. Therefore, apelin delayed the progression of RV hypertrophy and diastolic dysfunction. Together, these observations suggest that the apelin-APJ system may play an important role in the pathophysiology of PH, representing a potential therapeutic target since it significantly attenuates RV overload and PH-induced neurohumoral activation.
38
Characterization of Apelin, the Ligand for the APJ Receptor
Dennis K. Lee, Regina Cheng, Tuan Nguyen et al. · Journal of Neurochemistry · 2000 · 676 citations
The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism
Kazuhiko Tatemoto, Kiyoshige Takayama, Iku Kumaki et al. · Regulatory Peptides · 2001 · 643 citations
Medicine, Cardiology, Physiology +14